Caroline H Shiboski1, Stephen C Shiboski1, Raphaèle Seror2, Lindsey A Criswell1, Marc Labetoulle2, Thomas M Lietman1, Astrid Rasmussen3, Hal Scofield4, Claudio Vitali5, Simon J Bowman6, Xavier Mariette2. 1. University of California, San Francisco. 2. Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, INSERM U1184, Paris, France. 3. Oklahoma Medical Research Foundation, Oklahoma City. 4. Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, and Department of Veterans Affairs Medical Center, Oklahoma City. 5. Istituto Villa San Giuseppe, Como, Italy, and Casa di Cura di Lecco, Lecco, Italy. 6. University Hospitals Birmingham, NHS Foundation Trust, Birmingham, UK.
Abstract
OBJECTIVE: To develop and validate an international set of classification criteria for primary Sjögren's syndrome (SS) using guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These criteria were developed for use in individuals with signs and/or symptoms suggestive of SS. METHODS: We assigned preliminary importance weights to a consensus list of candidate criteria items, using multi-criteria decision analysis. We tested and adapted the resulting draft criteria using existing cohort data on primary SS cases and non-SS controls, with case/non-case status derived from expert clinical judgment. We then validated the performance of the classification criteria in a separate cohort of patients. RESULTS: The final classification criteria are based on the weighted sum of 5 items: anti-SSA/Ro antibody positivity and focal lymphocytic sialadenitis with a focus score of ≥1 foci/4 mm2 , each scoring 3; an abnormal ocular staining score of ≥5 (or van Bijsterveld score of ≥4), a Schirmer's test result of ≤5 mm/5 minutes, and an unstimulated salivary flow rate of ≤0.1 ml/minute, each scoring 1. Individuals with signs and/or symptoms suggestive of SS who have a total score of ≥4 for the above items meet the criteria for primary SS. Sensitivity and specificity against clinician-expert-derived case/non-case status in the final validation cohort were high, i.e., 96% (95% confidence interval [95% CI] 92-98%) and 95% (95% CI 92-97%), respectively. CONCLUSION: Using methodology consistent with other recent ACR/EULAR-approved classification criteria, we developed a single set of data-driven consensus classification criteria for primary SS, which performed well in validation analyses and are well-suited as criteria for enrollment in clinical trials.
OBJECTIVE: To develop and validate an international set of classification criteria for primary Sjögren's syndrome (SS) using guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These criteria were developed for use in individuals with signs and/or symptoms suggestive of SS. METHODS: We assigned preliminary importance weights to a consensus list of candidate criteria items, using multi-criteria decision analysis. We tested and adapted the resulting draft criteria using existing cohort data on primary SS cases and non-SS controls, with case/non-case status derived from expert clinical judgment. We then validated the performance of the classification criteria in a separate cohort of patients. RESULTS: The final classification criteria are based on the weighted sum of 5 items: anti-SSA/Ro antibody positivity and focal lymphocytic sialadenitis with a focus score of ≥1 foci/4 mm2 , each scoring 3; an abnormal ocular staining score of ≥5 (or van Bijsterveld score of ≥4), a Schirmer's test result of ≤5 mm/5 minutes, and an unstimulated salivary flow rate of ≤0.1 ml/minute, each scoring 1. Individuals with signs and/or symptoms suggestive of SS who have a total score of ≥4 for the above items meet the criteria for primary SS. Sensitivity and specificity against clinician-expert-derived case/non-case status in the final validation cohort were high, i.e., 96% (95% confidence interval [95% CI] 92-98%) and 95% (95% CI 92-97%), respectively. CONCLUSION: Using methodology consistent with other recent ACR/EULAR-approved classification criteria, we developed a single set of data-driven consensus classification criteria for primary SS, which performed well in validation analyses and are well-suited as criteria for enrollment in clinical trials.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: Tuhina Neogi; Daniel Aletaha; Alan J Silman; Raymond L Naden; David T Felson; Rohit Aggarwal; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Dinesh Khanna; Tore K Kvien; Timothy Laing; Katherine Liao; Philip Mease; Henri A Ménard; Larry W Moreland; Raj Nair; Theodore Pincus; Sarah Ringold; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker Journal: Arthritis Rheum Date: 2010-09
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope Journal: Arthritis Rheum Date: 2013-10-03
Authors: Troy E Daniels; Darren Cox; Caroline H Shiboski; Morten Schiødt; Ava Wu; Hector Lanfranchi; Hisanori Umehara; Yan Zhao; Stephen Challacombe; Mi Y Lam; Yvonne De Souza; Julie Schiødt; Helena Holm; Patricia A M Bisio; Mariana S Gandolfo; Toshioki Sawaki; Mengtao Li; Wen Zhang; Beni Varghese-Jacob; Per Ibsen; Alicia Keszler; Nozomu Kurose; Takayuki Nojima; Edward Odell; Lindsey A Criswell; Richard Jordan; John S Greenspan Journal: Arthritis Rheum Date: 2011-07
Authors: P Ghillani; C André; C Toly; A M Rouquette; D Bengoufa; P Nicaise; C Goulvestre; A Gleizes; M A Dragon-Durey; M A Alyanakian; P Chretien; S Chollet-Martin; L Musset; B Weill; C Johanet Journal: Autoimmun Rev Date: 2011-04-05 Impact factor: 9.754
Authors: C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita Journal: Arthritis Rheum Date: 1993-03
Authors: Astrid Rasmussen; John A Ice; He Li; Kiely Grundahl; Jennifer A Kelly; Lida Radfar; Donald U Stone; Kimberly S Hefner; Juan-Manuel Anaya; Michael Rohrer; Rajaram Gopalakrishnan; Glen D Houston; David M Lewis; James Chodosh; John B Harley; Pamela Hughes; Jacen S Maier-Moore; Courtney G Montgomery; Nelson L Rhodus; A Darise Farris; Barbara M Segal; Roland Jonsson; Christopher J Lessard; R Hal Scofield; Kathy L Moser Sivils Journal: Ann Rheum Dis Date: 2013-08-22 Impact factor: 19.103
Authors: Peter Olsson; Iris L A Bodewes; Anna M Nilsson; Carl Turesson; Lennart T H Jacobsson; Elke Theander; Marjan A Versnel; Thomas Mandl Journal: Rheumatol Int Date: 2019-05-28 Impact factor: 2.631
Authors: F Gulli; C Napodano; M Marino; G Ciasca; K Pocino; V Basile; M Visentini; A Stefanile; L Todi; M De Spirito; G L Rapaccini; U Basile Journal: Clin Exp Immunol Date: 2019-10-31 Impact factor: 4.330
Authors: Penny A Asbell; Maureen G Maguire; Ellen Peskin; Vatinee Y Bunya; Eric J Kuklinski Journal: Contemp Clin Trials Date: 2018-06-06 Impact factor: 2.226
Authors: John A Gonzales; Annie Chou; Jennifer R Rose-Nussbaumer; Vatinee Y Bunya; Lindsey A Criswell; Caroline H Shiboski; Thomas M Lietman Journal: Am J Ophthalmol Date: 2018-04-12 Impact factor: 5.258
Authors: Caroline H Shiboski; Alan N Baer; Stephen C Shiboski; Mi Lam; Stephen Challacombe; Hector E Lanfranchi; Morten Schiødt; Penelope Shirlaw; Muthiah Srinivasan; Hisanori Umehara; Frederick B Vivino; Esen Akpek; Vatinee Bunya; Cristina F Vollenweider; John S Greenspan; Troy E Daniels; Lindsey A Criswell Journal: Arthritis Care Res (Hoboken) Date: 2018-01-03 Impact factor: 4.794